Misplaced Pages

Oseltamivir

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by AnomieBOT (talk | contribs) at 19:39, 7 December 2014 (Rescuing orphaned refs ("cdc.gov" from rev 637052653; "Update on oseltamivir resistance to influenza H1N1 (2009) viruses" from rev 637052653)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 19:39, 7 December 2014 by AnomieBOT (talk | contribs) (Rescuing orphaned refs ("cdc.gov" from rev 637052653; "Update on oseltamivir resistance to influenza H1N1 (2009) viruses" from rev 637052653))(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Oseltamivir
Clinical data
Trade namesTamiflu
AHFS/Drugs.comMonograph
MedlinePlusa699040
License data
Pregnancy
category
  • AU: B1
Routes of
administration		oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Bioavailability>80%
Protein binding42% (parent drug), 3% (active metabolite)
MetabolismHepatic, to oseltamivir carboxylate
Elimination half-life1-3 hours, 6-10 hours (active metabolite)
ExcretionUrine (>90% as oseltamivir carboxylate), faeces
Identifiers
IUPAC name
  • ethyl (3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)-cyclohex-1-ene-1-carboxylate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H28N2O8P
Molar mass312.4 g/mol g·mol
3D model (JSmol)
SMILES
  • O=C(OCC)/C1=C/(OC(CC)CC)(NC(=O)C)(N)C1
InChI
  • InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1
  • Key:VSZGPKBBMSAYNT-RRFJBIMHSA-N
  (what is this?)  (verify)

Oseltamivir INN /ɒsəlˈtæmvɪər/, marketed under the trade name Tamiflu, is an antiviral medication used to prevent and treat influenza A and influenza B (flu). The drug is taken orally. Oseltamivir's risk-benefit ratio is controversial.

Two meta-analyses have concluded that benefits in those who are otherwise healthy do not outweigh its risks. While it reduces the duration of symptoms by a little less than a day one review found that it does not reduce serious complications among people seeking care for flu-like symptoms, though pneumonia was reduced among those infected with influenza. No evidence was found regarding whether treatment changes the risk of hospitalization in the elderly or other high risk populations, and that it is unclear if it affects rates of death. When the analysis was restricted to people with confirmed infection, a Cochrane review found unclear evidence of change in the risk of complications such as pneumonia. A systematic review of systematic reviews found that it prevented influenza, but recommended against its use in healthy, low risk persons due to cost, the risk of resistance development, and side effects. This review concluded it might be useful for prevention in high risk persons who had not been vaccinated. No evidence was found to support the usefulness of oseltamivir for the prevention of serious complications of influenza, as the trials were designed to demonstrate the more trivial outcome of "reduction of duration of symptoms" and were not designed or powered to evaluate impact on more clinically relevant outcomes. Side effects include psychiatric symptoms and increased rates of vomiting.

The Infectious Disease Society of America, the United States' Centers for Disease Control and Prevention, the European Centers for Disease Control, and the American Academy of Pediatrics continue to recommend the use of oseltamavir for people at high risk for complications and those at lower risk who present within 48 hours of first symptoms of infection. These organizations reject the Cochrane Collaboration conclusions, arguing that the analysis inappropriately forms conclusions about outcomes in people who are seriously ill based on results obtained primarily in healthy populations, and that the analysis inappropriately included results from patients not infected with influenza. Prior to 2013, oseltamivir's effectiveness was debated as its manufacturer, Roche, originally refused to release the data from all of its trials for independent analysis. Together, published studies suggest that oseltamivir reduces the duration of symptoms by 0.5–1 day. It is unclear whether this medication affects transmission of influenza in adults.

It was the first orally active neuraminidase inhibitor commercially developed. It was developed by C.U. Kim, W. Lew, and X. Chen of US-based Gilead Sciences, and is marketed by Genentech. Gilead licensed the exclusive rights to Roche in 1996. The starting material of the Tamiflu production process is shikimic acid. It is extracted from the pods of the Chinese star anise, grown in mountain provinces in the south west of China. It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.

Medical use

Oseltamivir is used for the prevention and treatment of influenza. When used for treatment or prevention in those that are otherwise healthy, it does not appear to have benefits that outweigh the risks. In other groups there is controversy regarding the efficacy of oseltamivir and its overall risk-benefit ratio.

Higher doses and longer durations of therapy have been suggested for treatment of people with the H5N1 virus.

There is low to moderate evidence that it decreases the risk of getting symptomatic influenza by 1% to 12% in those exposed. It is unclear whether it affects the risk of needing to be hospitalized or the risk of death. Oseltamivir was approved for the treatment and prevention of infections due to influenza A and B viruses. The predominant strains of both influenza A and influenza B active during the 2012-2013 flu season in the US were sensitive to oseltamivir.

Efficacy

A 2012 Cochrane review maintained that significant parts of the clinical trials remained unavailable for public scrutiny, and that the available evidence were not sufficient to conclude that oseltamivir decreases hospitalizations, complications or transmission from influenza-like illnesses. On April 10, 2014 Cochrane published an updated systematic review using all of the previously unreleased data, concluding that oseltamivir does not reduce hospitalizations, and that there is no proof of reduction of complications of influenza (such as pneumonia) because of a lack of diagnostic definitions, or reduction of the spread of the virus. They concluded that guidance should be revised to take account of the evidence of small benefit and increased risk of harms. Moreover the authors stated that their conclusions are similar to those reached by the U.S. FDA at the time of approval; that randomized clinical trial data supported the use of oseltamivir for the prevention and treatment of flu symptoms only, and didn't support claims of prevention of infection, transmission, or complications. There was also evidence that suggested that oseltamivir prevented some people from producing sufficient numbers of their own antibodies to fight infection.

Other groups, including the manufacturer, the United States and European Centers for Disease Control, Public Health England, the Infectious Disease Society of America, and the American Academy of Pediatrics have issued statements expressing disagreement with various aspects of the design of the Cochrane analysis as well as its conclusions.

Roche requested an independent reanalysis of its data in 2011. They concluded that early oseltamivir use for influenza-like illness reduced the number of "lower respiratory tract infection treated with antibiotics" in healthy adults and children.

The European Centers for Disease Control (ECDC) described the results of the Cochrane meta analysis as "an important signal event", but that the study by itself does not provide sufficient evidence to change treatment recommendations. The ECDC stated that it would convene an expert panel later in 2014 to review existing evidence for the efficacy of neuramidinase inhibitors.

The United States CDC continues to recommend oseltamivir for a number of uses. These recommendations are based in part on the results of observational studies that suggest that neurinamidase inhibitors reduced mortality in high risk patients. The CDC argues that the clinical trials included in meta analyses conducted by the Cochrane Collaboration and others include too few high risk patients to meaningfully examine the utility of neurinamidase inhibitors in preventing serious complications, and that multiple observational studies suggest reduced mortality in hospitalized and other high risk groups. One study cited by CDC is a large meta analysis of cohort studies of adult patients hospitalized during the 2009 H1N1 pandemic, which found a 19% reduction in mortality overall and a 50% reduction in mortality among adults treated within 48 hours of symptom onset. This study failed to find a statistically significant beneficial effect of treatment on survival in children and the study was funded by the manufacturer.

In April 2014, the Infectious Disease Society of America endorsed the CDC statement, and announced that it will continue to recommend neuramidase inhibitors for the treatment of influenza. The IDSA expressed concerns that the Cochrane analysis included both influenza virus-infected and non-infected subjects, and questioned the validity of using trial reports in patients with mild illness to direct treatment decisions for patients with severe illness or at high risk of influenza complications. The American Academy of Pediatrics issued a statement in 2014 echoing the IDSA's concerns. The AAP continues to recommend neuramidase inhibitors for the treatment of influenza.

Side effects

A package of capsules

Common adverse drug reactions (ADRs) associated with oseltamivir therapy (occurring in over 1 percent of clinical trial participants) include nausea and vomiting. In adults, oseltamivir increased the risk of nausea for which the number needed to harm was 28 and for vomiting was 22. So, for every 22 adult people on oseltamivir one experienced vomiting. In the treatment of children, oseltamivir also induced vomiting. The number needed to harm was 19. So, for every 19 children on oseltamivir one experienced vomiting. In prevention there were more headaches, kidney, and psychiatric events. Oseltamivir's effect on the heart is unclear: it may reduce cardiac symptoms, but may also induce serious heart rhythm problems.

Postmarketing reports include liver inflammation and elevated liver enzymes, rash, allergic reactions including anaphylaxis, toxic epidermal necrolysis, cardiac arrhythmia, seizure, confusion, aggravation of diabetes, and haemorrhagic colitis and Stevens–Johnson syndrome. The incidence of these adverse outcomes is unknown, and a causative role for oseltamivir has not been established.

Neuropsychiatric side effects

The 2014 Cochrane review found a dose-response effect on psychiatric events. In trials of prevention in adults one person was harmed for every 94 treated. This included events such as nervousness, aggression, hallucinations, psychosis, suicide ideation and paranoia. Neither of the two most cited published treatment trials of oseltamivir reported any drug-attributable serious adverse events.

The U.S. package insert for oseltamivir contains a warning of psychiatric effects observed in post-marketing surveillance. The frequency of these appears to be low and a casuative role for oseltamivir has not been established. The European Medicines Agency has added a similar warning.

Resistance

Influenza (flu)
H1N1 virus
Types
Vaccines
Treatment
Pandemics
Outbreaks
See also

The vast majority of mutations conferring resistance are single amino acid residue substitutions (His274Tyr in N1) in the neuraminidase enzyme. Meta-analysis of 15 studies found a pooled incidence rate for oseltamivir resistance of 2.6%. Subgroup analyses detected higher incidence rates among influenza A patients, especially for H1N1 subtype influenza. It was found that a substantial number of patients might become oseltamivir-resistant as a result of oseltamivir use, and that oseltamivir resistance might be significantly associated with pneumonia. In contrast, zanamivir resistance has been rarely reported to date. In severely immunocompromised patients there were reports of prolonged shedding of oseltamivir- (or zanamivir)-resistant virus, even after oseltamivir treatment was stopped.

2009 pandemic H1N1 flu or "Swine flu"

As of December 15, 2010, the World Health Organization (WHO) reported 314 samples of the prevalent 2009 pandemic H1N1 flu tested worldwide have shown resistance to oseltamivir.

During 2011 a new influenza A(H1N1)2009 variant with mildly reduced oseltamivir (and zanamivir) sensitivity was detected in more than 10% of community specimens in Singapore and more than 30% of samples from northern Australia.

The CDC found sporadic oseltamivir-resistant 2009 H1N1 virus infections had been identified, including with rare episodes of limited transmission, but the public health impact had been limited. Those sporadic cases of resistance were found in immunosuppressed patients during oseltamivir treatment and persons who developed illness while receiving oseltamivir chemoprophylaxis.

There is concern that antiviral resistance will develop in people with haematologic malignancies due to their inability to reduce viral loads. Several surveillance studies found oseltamivir resistant pH1N1 after administration of oseltamivir in those people, however widespread transmission of oseltamivir-resistant pH1N1 did not occur.

Seasonal flu

Resistance to Oseltamivir was widespread in seasonal flu from 2007-2009. In the 2007-2008 flu season, the US CDC found 10.9% of H1N1 samples (n=1,020) to be resistant. In the 2008-2009 season, the proportion of resistant H1N1 increased to 99.4%. Other seasonal strains (H3N2, B) showed no resistance. All Oseltamivir-resistant strains maintained sensitivity to zanamivir.

Resistance to Oseltamivir has been low in seasonal flu from 2009-2012. In the 2010-2011 flu season, the US CDC reported maintained Oseltamivir sensitivity in 99.1% of H1N1, 99.8% of H3N, and 100% of Influenza B. As of January 2012, the US and European CDCs were reporting sensitivity to Oseltamivir for all seasonal flu samples tested since October 2011. In the US in the season 2013-2014 only 1% of 2009 H1N1 viruses have shown resistance to oseltamivir. No other influenza viruses have shown resistance to oseltamivir.

H3N2

Mutant H3N2 influenza A virus isolates resistant to oseltamivir were found in 18 percent of a group of 50 Japanese children treated with oseltamivir in 2002-2003. Several explanations were proposed by the authors of the studies for the higher-than-expected resistance rate detected. First, children typically have a longer infection period, giving a longer time for resistance to develop. Second, Kiso et al. claim to have used more rigorous detection techniques than previous studies. Inadequate dosage may also have been an issue.

Influenza B

In 2007, Japanese investigators detected neuraminidase-resistant influenza B virus strains in individuals having not been treated with these drugs. The prevalence was 1.7 percent. According to the CDC, as of October 3, 2009 no influenza B strains tested have shown any resistance to oseltamivir.

H5N1 Avian influenza "Bird flu"

High-level resistance has been detected in one girl suffering from H5N1 avian influenza in Vietnam. She was being treated with oseltamivir at time of detection. de Jong et al. (2005) describe resistance development in two more Vietnamese patients suffering from H5N1, and compare their cases with six others. They suggest the emergence of a resistant strain may be associated with a patient's clinical deterioration. They also note that the recommended dosage of oseltamivir does not always completely suppress viral replication, a situation that could favor the emergence of resistant strains. Moscona (2005) gives a good overview of the resistance issue, and says that personal stockpiles of oseltamivir could lead to underdosage and, thus, the emergence of resistant strains of H5N1.

Resistance is of concern in the scenario of an influenza pandemic (Wong and Yuen 2005), and may be more likely to develop in avian influenza than seasonal influenza due to the potentially longer duration of infection by novel viruses. Kiso et al. suggest "a higher prevalence of resistant viruses should be expected" during a pandemic. Resistant strains have also appeared in the EU.

Established markers of neuraminidase inhibitor resistance were found in 2.4% of human and 0.8% of avian isolates of H5N1 influenza.

H7N9 Avian influenza

There was emergence of oseltamivir-resistant virus with the Arg292Lys mutation in two patients among 14 adults infected with A(H7N9) during treatment with oseltamivir.

Mechanism of action

The prodrug oseltamivir is itself not virally effective; however, once in the liver it is hydrolysed to its active metabolite - the free oseltamivir carboxylate.

Oseltamivir is a neuraminidase inhibitor, serving as a competitive inhibitor of the activity of the viral neuraminidase (NA) enzyme upon sialic acid, found on glycoproteins on the surface of normal host cells. By blocking the activity of the enzyme, oseltamivir prevents new viral particles from being released through the cleaving of terminal sialic acid on glycosylated hemagglutinin and thus fail to facilitate virus release.

Pharmacokinetics

Its oral bioavailability is over 80% and is extensively metabolised to its active form upon first-pass through the liver. It has a volume of distribution of 23-26 litres. Its half-life is about 1–3 hours and its active metabolite has a half-life of 6–10 hours. It is predominantly eliminated in the urine as the active carboxylate metabolite (>90% of oral dose).

History

Plate from François-Pierre Chaumeton's 1833 "Flore Medicale"

Around 40 Hoffman-LaRoche sponsored randomised clinical trials of oseltamivir were completed around the end of the nineties. In October 1999 and November 2000 FDA approved oseltamivir for treatment and profylaxis of influenza. In June 2002 EMA approved oseltamivir for prophylaxis and treatment of influenza. In 2003 the Kaiser pooled analysis of 10 randomised clinical trials concluded that oseltamivir reduced the risk of lower respiratory tract infections resulting in antibiotic use and hospital admissions in adults. From 2004 governments around the world began stockpiling oseltamivir by fears of avian influenza H5N1. In January 2006 a Cochrane review concluded that oseltamivir reduced complications such as pneumonia. The Kaiser 2003 paper drove the result in the meta-analysis. In 2009 a new A/H1N1 influenza virus was discovered to be spreading in North America. In June 2009 WHO declared the A/H1N1 influenza a “pandemic”. The CDC, WHO, and the European Centre for Disease Prevention claimed the effectiveness of oseltamivir against complications, which caused governments around the world to stockpile these drugs in case of a pandemic. Also in 2009 NICE advised them to use in people at risk for complications. From 2010 to 2012 Cochrane in vain requested the full clinical study reports of their trials to Roche, but in 2011 a freedom of information request to the European Medicines Agency provided them with the clinical study reports from 16 Roche oseltamivir trials. In 2012 the Cochrane team published the interim version of the Cochrane review based on EMA’s incomplete clinical study reports, but in 2013 Roche released 77 full clinical study reports of oseltamivir trials, after GSK released the data on zanamivir studies. In 2014 Cochrane published an updated review based solely on full clinical study reports and regulatory documents. In the mean time buying a strategic reserve of Tamiflu the US has spent more than $1.3 billion. In 2013 the UK National Audit Office, said that the government spent £560m (€670; $930m) on antivirals for stockpiling between 2006 and 2013: £424m on oseltamivir and £136m on zanamivir. After the Cochrane analysis EMA stated that it did not alter the Agency's view that the benefits of oseltamivir outweighed its risks. The US Centers for Disease Control continued to recommend the use of oseltamavir treatment for people at high risk for complications and those at lower risk who present within 48 hours of first symptoms. NICE considers to review its guidance on using of oseltamivir in light of the new Cochrane findings.

Commercial issues

The patent for oseltamivir is held by Gilead Sciences and is valid at least until 2016. Gilead licensed the exclusive rights to Roche in 1996. The drug does not enjoy patent protection in Thailand, the Philippines, Indonesia, and several other countries.

Oseltamivir was widely used during the H5N1 avian influenza epidemic in Southeast Asia in 2005. In response to the epidemic, various governments – including those of the United Kingdom, Canada, Israel, United States, and Australia – stockpiled quantities of oseltamivir in preparation for a possible pandemic.

In late October 2005, Roche announced it was suspending shipments to pharmacies in the United States and Canada until the North American seasonal flu outbreak began, to address concerns about private stockpiling and to preserve supplies for seasonal influenza. Sales were suspended in Hong Kong as well, and on November 8, 2005, also in China. Roche said it would instead send all supplies to China's health ministry.

On November 9, 2005, Vietnam became the first country to be granted permission by Roche to produce a generic version of oseltamivir. The week before, Thai authorities said they would begin producing generic oseltamivir, claiming that Roche had not patented Tamiflu in Thailand. The first Thai generic oseltamivir was produced in February 2006, and was to have been available to the public in July 2006.

In November 2005, U.S. President George W. Bush requested that Congress fund US$1 billion for the production and stockpile of oseltamivir, after Congress had already approved $1.8 billion for military use of the drug. Defense Secretary Rumsfeld recused himself from all government decisions regarding the drug.

In December 2005, Roche signed a sublicense for complete oseltamivir production with China's Shanghai Pharmaceuticals, and by March 2006, a sublicense had also been granted to India's Hetero.

In May 2006, the WHO asked Roche to be ready to ship an emergency stockpile of oseltamivir to Indonesia if needed. The alert was in response to suspected human-to-human transmission within a family, and was planned to last for two weeks.

In December 2008, the Indian drug company, Cipla won its case in India's court system allowing it to manufacture a cheaper generic version of Tamiflu, called Antiflu. In May 2009, Cipla won approval from the WHO certifying that its drug Antiflu was as effective as Tamiflu, and Antiflu is included in the WHO list of prequalified medicinal products.

Marketing display used at festivals features a person living in a hermetically sealed environment

Production shortage/shikimic acid

In early 2005, Roche announced a production shortage. In 2006, however, Roche said production was about to reach 400-million treatment courses annually, that "capacity was well in excess of total government orders placed to date," and "the supply shortage no longer exists." Total government orders between 2005 and 2007 were estimated to be around 200 million treatment doses. In fact, Roche CEO William Burns said a shortage of orders could cause Roche to reduce production in the future. Roche attributes production increases in part to its agreements with 15 external contractors in 9 countries.

Personal stockpiling

A short supply of oseltamivir prompted some individuals to stockpile the drug. Several American states issued advisories strongly discouraging this practice.

In The New England Journal of Medicine, Anne Moscona (2005) argues that the use of personal stockpiles of oseltamivir could result in the administration of low dosages, allowing for the development of drug-resistant virus strains. Many stockpilers will have only ten pills of 75 mg each (the current recommended dosage for oseltamivir), but this may be insufficient for the treatment of H5N1.

Another argument against individual stockpiling is that limited drugs should be kept for more strategic deployment, that is, to hard-hit areas, to people in critical roles (e.g., healthcare and government workers), to people vulnerable to seasonal flu, or to people having come down with avian influenza. Ethical arguments are sometimes made as to whether affluent people or nations should have preferred access to antiviral medications. Illegal importation might divert the drug from poorer countries, where the risk of avian influenza is actually higher. A counter argument is that it is difficult to justify prohibition of individual stockpiling, when some of the same arguments are pertinent to corporate stockpiling, which is both allowed and encouraged.

A third argument is that it would be difficult for home users to determine whether illegally imported Tamiflu is counterfeit. In December 2005, 53 packages of counterfeit Tamiflu tablets were intercepted by the US Customs Service in South San Francisco. The packages were labeled "Generic Tamiflu". Roche officials know of only one instance of the appearance of counterfeit Tamiflu outside of the United States: incorrectly labeled tablets found in the Netherlands, which contained only vitamin C and lactose.

An argument in favour of individual stockpiling is that Roche is on the record as saying that, without more orders, they may have to actually curtail production. Individual stockpiling could bring market forces to play, maintaining production capacity and allowing the total supply on hand to be higher in case demand again outstrips production in the future, for instance, during a sudden influenza outbreak.

Veterinary use

There have been reports of oseltamivir's reducing disease severity and hospitalization time in canine parvovirus infection. The drug may limit the ability of the virus to invade the crypt cells of the small intestine and decrease gastrointestinal bacterial colonization and toxin production.

Manufacturing

Oseltamivir is marketed by Genentech under the trade name Tamiflu, as capsules (containing oseltamivir phosphate 98.5 mg equivalent to oseltamivir 75 mg) and as a powder for oral suspension (oseltamivir phosphate equivalent to oseltamivir 6 mg/ml).

See also

References

  1. ^ Davies, BE (April 2010). "Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations" (PDF). The Journal of antimicrobial chemotherapy. 65 Suppl 2: ii5 – ii10. doi:10.1093/jac/dkq015. PMC 2835511. PMID 20215135.
  2. ^ Burch J; Corbett M; Stock C; et al. (September 2009). "Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis". Lancet Infect Dis. 9 (9): 537–45. doi:10.1016/S1473-3099(09)70199-9. PMID 19665930. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  3. ^ Coenen, B; Van Puyenbroeck, K; Verhoeven, V; Vermeire, E; Coenen, S; Verhoeven, Veronique; Vermeire, Etienne; Coenen, Samuel (2013). Jefferson, Tom (ed.). "The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews". PLoS ONE. 8 (4): e60348. Bibcode:2013PLoSO...860348M. doi:10.1371/journal.pone.0060348. PMC 3614893. PMID 23565231.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link) Cite error: The named reference "Mich2013" was defined multiple times with different content (see the help page).
  4. ^ Ebell, MH; Call, M; Shinholser, J (April 2013). "Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials". Family practice. 30 (2): 125–33. doi:10.1093/fampra/cms059. PMID 22997224.
  5. ^ Jefferson T, Jones MA, Doshi P; Doshi; Del Mar; Hama; Thompson; Spencer; Onakpoya; Mahtani; Nunan; Howick; Heneghan; et al. (2014). "Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children". Cochrane Database Syst Rev. 4: CD008965. doi:10.1002/14651858.CD008965.pub4. PMID 24718923. {{cite journal}}: Explicit use of et al. in: |author2= (help); Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)CS1 maint: multiple names: authors list (link)
  6. Wang K, Shun-Shin M, Gill P, Perera R, Harnden A; Shun-Shin; Gill; Perera; Harnden (2012). Harnden, Anthony (ed.). "Neuraminidase inhibitors for preventing and treating influenza in children (published trials only)". Cochrane Database Syst Rev. 4: CD002744. doi:10.1002/14651858.CD002744.pub4. PMID 22513907.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  7. Jefferson, T; Jones, M; Doshi, P; Spencer, EA; Onakpoya, I; Heneghan, CJ (Apr 9, 2014). "Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments". BMJ (Clinical research ed.). 348: g2545. doi:10.1136/bmj.g2545. PMC 3981975. PMID 24811411.
  8. ^ "CDC Online Newsroom - "Have You Heard?" Archive: 2014 - Influenza A Variant Virus".
  9. ^ "Recommendations for Prevention and Control of Influenza in Children, 2014-2015". Pediatrics. September 2014. doi:10.1542/peds.2014-2413. PMID 25246619.
  10. ^ "ECDC Reviews - New and updated evaluations of neuraminidase..."
  11. ^ "IDSA : IDSA Continues to Recommend Antivirals for Influenza". Retrieved April 24, 2014.
  12. "Recommendations for Prevention and Control of Influenza in Children, 2014-2015". Pediatrics. September 2014. doi:10.1542/peds.2014-2413. PMID 25246619.
  13. Agrawal, R; Rewatkar, PV; Kokil, GR; Verma, A; Kalra, A (Jul 2010). "Oseltamivir: a first line defense against swine flu". Medicinal chemistry (Shariqah (United Arab Emirates)). 6 (4): 247–51. PMID 20843284.
  14. Kim, CU; Lew, W; Williams, MA; Liu, H; Zhang, L; Swaminathan, S; Bischofberger, N; Chen, MS; Mendel, DB; Tai, CY; Laver, WG; Stevens, RC (Jan 29, 1997). "Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity". Journal of the American Chemical Society. 119 (4): 681–90. doi:10.1021/ja963036t. PMID 16526129.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  15. Lew W, Chen X, Kim CU; Chen; Kim (June 2000). "Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor". Curr. Med. Chem. 7 (6): 663–72. doi:10.2174/0929867003374886. PMID 10702632.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  16. "Tamiflu Approval, Review, and Labeling Information". Drugs@FDA. U.S. Food and Drug Administration (FDA). Archived from the original on 2011-05-21. Retrieved 2012-11-08.
  17. Wang, Guo-Wei; Hu, Wen-Ting; Huang, Bao-Kang; Qin, Lu-Ping (June 2011). "Illicium verum: A review on its botany, traditional use, chemistry and pharmacology". Journal of Ethnopharmacology. 136 (1): 10–20. doi:10.1016/j.jep.2011.04.051. PMID 21549817.
  18. "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
  19. "Tamiflu". The American Society of Health-System Pharmacists. Retrieved Dec 12,2014, 2014. {{cite web}}: Check date values in: |accessdate= (help)
  20. ^ Ward, P; Small, I; Smith, J; Suter, P; Dutkowski, R (February 2005). "Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic". The Journal of antimicrobial chemotherapy. 55 Suppl 1: i5 – i21. PMID 15709056.
  21. Tamiflu (oseltamivir phosphate) Information U.S. Food and Drug Administration (FDA)
  22. http://www.cdc.gov/flu/about/qa/antiviralresistance.htm#antiviral-drugs
  23. Belluz J (2014). "Tug of war for antiviral drugs data". BMJ. 348: g2227. doi:10.1136/bmj.g2227. PMID 24811408.
  24. "Drug Approval Package: Tamiflu (Oseltamivir Phosphate) NDA# 021087".
  25. "www.gov.uk" (PDF).
  26. ^ Hernán MA, Lipsitch M; Lipsitch (August 2011). "Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials". Clin. Infect. Dis. 53 (3): 277–9. doi:10.1093/cid/cir400. PMC 3137795. PMID 21677258.
  27. Muthuri, Stella G; Venkatesan, Sudhir; Myles, Puja R; Leonardi-Bee, Jo; Al Khuwaitir, Tarig S A; Al Mamun, Adbullah; Anovadiya, Ashish P; Azziz-Baumgartner, Eduardo; Báez, Clarisa; Bassetti, Matteo; Beovic, Bojana; Bertisch, Barbara; Bonmarin, Isabelle; Booy, Robert; Borja-Aburto, Victor H; Burgmann, Heinz; Cao, Bin; Carratala, Jordi; Denholm, Justin T; Dominguez, Samuel R; Duarte, Pericles A D; Dubnov-Raz, Gal; Echavarria, Marcela; Fanella, Sergio; Gao, Zhancheng; Gérardin, Patrick; Giannella, Maddalena; Gubbels, Sophie; Herberg, Jethro; Iglesias, Anjarath L Higuera; Hoger, Peter H; Hu, Xiaoyun; Islam, Quazi T; Jiménez, Mirela F; Kandeel, Amr; Keijzers, Gerben; Khalili, Hossein; Knight, Marian; Kudo, Koichiro; Kusznierz, Gabriela; Kuzman, Ilija; Kwan, Arthur M C; Amine, Idriss Lahlou; Langenegger, Eduard; Lankarani, Kamran B; Leo, Yee-Sin; Linko, Rita; Liu, Pei; Madanat, Faris; Mayo-Montero, Elga; McGeer, Allison; Memish, Ziad; Metan, Gokhan; Mickiene, Auksė; Mikić, Dragan; Mohn, Kristin G I; Moradi, Ahmadreza; Nymadawa, Pagbajabyn; Oliva, Maria E; Ozkan, Mehpare; Parekh, Dhruv; Paul, Mical; Polack, Fernando P; Rath, Barbara A; Rodríguez, Alejandro H; Sarrouf, Elena B; Seale, Anna C; Sertogullarindan, Bunyamin; Siqueira, Marilda M; Skręt-Magierło, Joanna; Stephan, Frank; Talarek, Ewa; Tang, Julian W; To, Kelvin K W; Torres, Antoni; Törün, Selda H; Tran, Dat; Uyeki, Timothy M; Van Zwol, Annelies; Vaudry, Wendy; Vidmar, Tjasa; Yokota, Renata T C; Zarogoulidis, Paul; Nguyen-Van-Tam, Jonathan S; Myles, Puja R; Leonardi-Bee, Jo; Al Khuwaitir, Tarig S A; Al Mamun, Adbullah; Anovadiya, Ashish P; Azziz-Baumgartner, Eduardo; Báez, Clarisa; Bassetti, Matteo; Beovic, Bojana; Bertisch, Barbara; Bonmarin, Isabelle; Booy, Robert; Borja-Aburto, Victor H; Burgmann, Heinz; Cao, Bin; Carratala, Jordi; Denholm, Justin T; Dominguez, Samuel R; Duarte, Pericles A D; Dubnov-Raz, Gal; Echavarria, Marcela; Fanella, Sergio; Gao, Zhancheng; Gérardin, Patrick; Giannella, Maddalena; Gubbels, Sophie; Herberg, Jethro; et al. (March 2014). "Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data". The Lancet Respiratory Medicine. 2 (5): 395–404. doi:10.1016/S2213-2600(14)70041-4. PMID 24815805.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  28. ^ Tamiflu Prescribing Information
  29. Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.
  30. ^ Cohen, D. (9 April 2014). "Oseltamivir: another case of regulatory failure?". BMJ. 348 (apr09 8): g2591 – g2591. doi:10.1136/bmj.g2591.
  31. Waknine, Yael (2006). "Tamiflu May Be Linked to Risk for Self-Injury and Delirium". Medscape. Retrieved 17 May 2008.
  32. "Pediatric safety update for Tamiflu". U.S. Food and Drug Administration (FDA)
  33. Thorlund, Kristian; Awad, Tahany; Boivin, Guy; Thabane, Lehana (2011). "Systematic review of influenza resistance to the neuraminidase inhibitors". BMC Infectious Diseases. 11 (1): 134. doi:10.1186/1471-2334-11-134.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  34. ^ "Antiviral Drug Resistance among Influenza Viruses Guidance on the Use of Influenza Antiviral Agents (Current for the 2013-14 Influenza Season)". CDC. Retrieved 21 April 2014.
  35. "Update on oseltamivir resistance to influenza H1N1 (2009) viruses" (PDF). World Health Organization (WHO). December 15, 2010. Retrieved December 30, 2010.
  36. Hurt, A.C. (9 June 2011). "Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation". Eurosurveillance.
  37. Downing, Mark. "Antiviral Therapy for Pandemic Influenza A (H1N1) Infection: Dosing, Combination Therapy, and Resistance" (PDF). National collaborating centre for infectious diseases.
  38. http://www.cdc.gov/flu/weekly/weeklyarchives2007-2008/07-08summary.htm
  39. http://www.cdc.gov/flu/weekly/weeklyarchives2008-2009/08-09summary.htm
  40. http://www.cdc.gov/flu/weekly/weeklyarchives2010-2011/10-11summary.htm
  41. http://www.cdc.gov/flu/weekly/weeklyarchives2011-2012/weekly51.htm
  42. http://www.ecdc.europa.eu/en/publications/Publications/111230_SUR_Weekly_Influenza_Surveillance_Overview.pdf
  43. "CDC Influenza Division Key Points March 28, 2014" (PDF). CDC. Retrieved 15 April 2014.
  44. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 15337401, please use {{cite journal}} with |pmid=15337401 instead.
  45. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 17405969, please use {{cite journal}} with |pmid=17405969 instead.
  46. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 16228009, please use {{cite journal}} with |pmid=16228009 instead.
  47. "WHO intercountry-consultation. Influenza A/H5N1 in humans in Asia. Manila, Philippines, 6–7 May 2005". World Health Organization. May 2005.
  48. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 16371626, please use {{cite journal}} with |pmid=16371626 instead.
  49. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ; Haire; Lin; Liu; Russell; Walker; Skehel; Martin; Hay; Gamblin (June 2008). "Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants". Nature. 453 (7199): 1258–61. Bibcode:2008Natur.453.1258C. doi:10.1038/nature06956. PMID 18480754.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  50. Garcia-Sosa AT, Sild S, Maran U; Sild; Maran (October 2008). "Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant". J. Chem. Inf. Model. 48 (10): 2074–80. doi:10.1021/ci800242z. PMID 18847186.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  51. Govorkova, Elena A.; Baranovich, Tatiana; Seiler, Patrick; Armstrong, Jianling; Burnham, Andrew; Guan, Yi; Peiris, Malik; Webby, Richard J.; Webster, Robert G. (May 2013). "Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002–2012 shows need for continued monitoring". Antiviral Research. 98 (2): 297–304. doi:10.1016/j.antiviral.2013.02.013. PMC 3648604. PMID 23458714. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
  52. Hay, Alan J; Hayden, Frederick G (June 2013). "Oseltamivir resistance during treatment of H7N9 infection". The Lancet. 381 (9885): 2230–2232. doi:10.1016/S0140-6736(13)61209-X.
  53. Kaiser, L; Wat, C; Mills, T; Mahoney, P; Ward, P; Hayden, F (Jul 28, 2003). "Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations". Archives of Internal Medicine. 163 (14): 1667–72. doi:10.1001/archinte.163.14.1667. PMID 12885681.
  54. ^ Jefferson, T.; Doshi, P. (10 April 2014). "Multisystem failure: the story of anti-influenza drugs". BMJ. 348 (apr10 14): g2263 – g2263. doi:10.1136/bmj.g2263.
  55. "WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses Revised February 2010" (PDF). WHO.
  56. "Amantadine, oseltamivir and zanamivir for the treatment of influenza (review of existing guidance No. 58)". NICE. 2009.
  57. Cohen, D. (4 April 2013). "Roche offers researchers access to all Tamiflu trials". BMJ. 346 (apr04 3): f2157 – f2157. doi:10.1136/bmj.f2157.
  58. "Researchers, regulators and Roche row over stockpiled drug Tamiflu | Reuters".
  59. Price, Caroline (10 April 2014). "Gold standard review casts further doubt on benefit of antivirals for flu". Pulse. Retrieved 19 April 2014.
  60. Avian Flu Drugs: Patent Questions, WIPO Magazine, April 2006
  61. "Roche to suspend Tamiflu shipments to US private sector". Forbes. AFX News Limited. 2005-10-27. Archived from the original on 2009-05-13. Retrieved 2009-07-29.
  62. "Man dies of bird flu in Vietnam". Gulf Times. 2005-11-09. Retrieved 2009-09-27.
  63. Tran Van Minh (2005-11-09). "Vietnam to produce generic bird-flu drug". The Washington Post. Associated Press. Retrieved 2009-07-29.
  64. Le Thang Long (2005-11-10). "Roche lets Vietnam make Tamiflu". The Standard. Retrieved 2009-07-29.
  65. Shannon Brownlee and Jeanne Lenzer (November 2009) "Does the Vaccine Matter?", The Atlantic
  66. "China-made Tamiflu approved for production". People's Daily. 2006-06-13. Retrieved 2009-07-29.
  67. McCoy, Michael (2006-03-20). "Making Tamiflu". Chemical & Engineering News. Retrieved 2009-07-29.
  68. "WHO puts Tamiflu maker on alert after suspected human-to-human transmission". Medical News Today. 2006-05-27. Retrieved 2009-07-29.
  69. "Cipla's anti-flu drug gets nod". Times of India. 2009-05-14. Retrieved 2009-07-29.
  70. ^ "Tamiflu readily available for 2006/2007 influenza season" (Press release). Roche. 2006-10-02. Retrieved 2009-07-29.
  71. ^ "Roche boosts Tamiflu production; CDC cites signs of hoarding". CIDRAP. 2006-03-16. Retrieved 2009-07-29.
  72. "Roche update on Tamiflu for pandemic influenza preparedness" (Press release). 2006-03-16. Retrieved 2009-07-29.
  73. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 16371632, please use {{cite journal}} with |pmid=16371632 instead.
  74. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 15070787, please use {{cite journal}} with |pmid=15070787 instead.
  75. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 20230441, please use {{cite journal}} with |pmid=20230441 instead.
  76. Macintire, Douglass K. (2006). "Treatment of Parvoviral Enteritis". Proceedings of the Western Veterinary Conference. Retrieved 2007-06-09.
  77. Tamiflu Prescribing InformationU.S. Food and Drug Administration (FDA)

Further reading

  • Pollack, Andrew (November 5, 2005). "Is Bird Flu Drug Really So Vexing? Debating the Difficulty of Tamiflu". The New York Times.
  • Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 16424427, please use {{cite journal}} with |pmid=16424427 instead.
  • Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1021/jo980330q, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1021/jo980330q instead.
  • Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1021/jo005702l, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1021/jo005702l instead.
  • Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.2533/000942904777677605, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.2533/000942904777677605 instead.
  • Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1021/ja0616433, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1021/ja0616433 instead.
  • Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 1951305, please use {{cite journal}} with |pmid=1951305 instead.

External links

RNA virus antivirals (primarily J05, also S01AD and D06BB)
Hepatitis C
NS3/4A protease inhibitors (–previr)
NS5A inhibitors (–asvir)
NS5B RNA polymerase inhibitors (–buvir)
Combination drugs
Hepatitis D
Picornavirus
Anti-influenza agents
Multiple/general
Interferon
3CL protease inhibitors (–trelvir)
RNA pol inhibitors
Multiple/Unknown/Other
Influenza
General topics
Viruses
Influenza A virus
subtypes
H1N1
Pandemics
Science
H5N1
Outbreaks
Science
H5N8
Outbreaks
Treatments
Antiviral drugs
Vaccines
Pandemics and
epidemics
Pandemics
Epidemics
Non-human
Mammals
Non-mammals
Complications
Related topics
2009 swine flu pandemic
Outbreak timeline · Pandemic tables
Location
Africa
Asia
Europe
North America
South America
Oceania
Related
See also: Spanish flu, H5N1, Bird flu, and Influenza-like illness
Categories: